Serodus ASA announced its plan to merge with Phlogo ApS. The merger would enable Serodus to speed up its commercialization and development strategies.

Through the merger, Serodus would add two first-in-class drug candidates, namely, SER130 and SER140. According to Serodus CEO Eva Steiness: "Phlogo's peptides SER130 and SER140 come from internationally-recognized researchers at Copenhagen University who have been concentrating on mimicking and inhibiting endogenous inflammatory cascades. SER130 improves our portfolio in Serodus' core cardiovascular therapeutic drug development field by focusing on the severe tissue damage, which occurs after a heart attack. SER140 is also an interesting anti-inflammatory drug candidate, but targeted at diabetes, which is outside Serodus' main focus, and we will therefore be seeking a partner to continue its development."

Phlogo CEO, Torben Skarsfeldt, said that he was pleased with the merger agreement with Serodus. "Phlogo has generated very interesting data on both compounds, but we were in a position where the company needed additional resources to continue the development. We are confident that Serodus can bring these projects forward," he added.